In the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis, PR expression was not significantly predictive of tamoxifen treatment response in ER-negative breast cancer, although there was a slight trend, which failed to reach statistical significance [ 14 ].
← all excerpts
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.
2
—
—
The sentences
The recent EBCTG meta-analysis of randomized trials of tamoxifen efficacy identified a slight trend for PR expression to be associated with benefit from tamoxifen therapy in ER- breast cancer; although this result did not reach statistical significance [ 14 ].